Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNGCAD)

• Drug Name: Rova-T Drug Info
• Synonyms: rovalpituzumab tesirine; Rovalpituzumab Tesirine; Rova-t; Rovalpituzumab-Tesirin; UNII-P256HB60FF; Rovalpituzumab tesirine [INN]; P256HB60FF; Rovalpituzumab tesirine [WHO-DD]; Rovalpituzumab tesirine [USAN:INN]; SC0002; 1613313-09-9

Indication

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Phase 3	[1]
Neuroendocrine cancer	2B72.1	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 131954443
  CAS Number: CAS 1613313-09-9
  TTD Drug ID: DMNGCAD

Molecule-Related Drug Atlas

Drug(s) Targeting Delta-like protein 3 (DLL3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[3]
HPN328	DM1ZHML	Small-cell lung cancer	2C25.Y	Phase 1/2	[4]
AMG 757	DMLYP2N	Neuroendocrine cancer	2B72.1	Phase 1	[5]
AMG 119	DMKF1O2	Small-cell lung cancer	2C25.Y	Phase 1	[5]
RG6524	DMT22UV	Aggressive cancer	2A00-2F9Z	Phase 1	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Delta-like protein 3 (DLL3)	TT1C9K6	DLL3_HUMAN	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
• [4] Clinical pipeline report, company report or official report of Harpoon Therapeutics.
• [5] Clinical pipeline report, company report or official report of Amgen.
• [6] Clinical pipeline report, company report or official report of Roche